Prazosin for Nightmares: Clinical Recommendation
Prazosin can be used to treat PTSD-related nightmares and is recommended as the first-line pharmacologic option, though recent evidence has downgraded this recommendation from Level A to a more cautious stance due to conflicting trial results.
Evidence Quality and Recommendation Strength
The American Academy of Sleep Medicine initially gave prazosin a Level A recommendation for PTSD-associated nightmares in 2010 1. However, the 2018 position paper downgraded this recommendation after a large VA study of 304 participants showed no significant benefit over placebo at 26 weeks 2. Despite this, the Task Force unanimously agreed that prazosin remains the first choice for pharmacologic therapy because many patients respond very well clinically 2.
The most recent meta-analysis (2020) supports prazosin's efficacy specifically for nightmares (SMD = -1.13, p<0.01), though not for overall PTSD symptoms or general sleep quality 3.
Dosing Protocol
Initial Dosing
- Start at 1 mg at bedtime 1
- This minimizes the risk of first-dose syncope, which occurs in approximately 1% of patients starting at 2 mg or higher 4
- Never use 2 mg or 5 mg capsules for initial therapy 4
Titration Schedule
- Increase by 1-2 mg every few days based on nightmare response and tolerability 1
- Monitor for orthostatic hypotension after each dose increase
Target Dosing
- Average effective dose: 3 mg/day for civilians 1
- Higher doses for military/combat PTSD: 9.5-15.6 mg/day (mean 13.3 mg for men, 7.0 mg for women) 2
- Effective range: 1-20 mg, though some patients may require up to 40 mg 4
- Treatment response typically occurs within 3-9 weeks 1
Monitoring Requirements
Blood Pressure Monitoring
- Check orthostatic vital signs 30-90 minutes after first dose (when syncope risk is highest) 4
- Monitor blood pressure with each dose escalation
- Watch for symptomatic hypotension, dizziness, or lightheadedness 4
Clinical Response Assessment
- Use CAPS "distressing dreams" item (Item #2) to track nightmare frequency and intensity 1, 2
- Expect reduction from baseline scores of 4.8-6.9 to 3.2-3.6 with effective treatment 1
- Monitor sleep quality, daytime fatigue, and overall PTSD symptoms
Critical Clinical Considerations
Drug Interactions
Concurrent antidepressant use may reduce prazosin efficacy 2. In the 2013 active-duty soldier trial, patients on SSRIs had significantly less response (CAPS decrease 9.6 vs 30.1 in those not on SSRIs) 2. The large negative VA trial had 78% of participants on maintenance antidepressants 2.
Contraindications and Precautions
- Avoid in patients taking PDE-5 inhibitors (additive hypotensive effects) 4
- Use caution with beta-blockers (increased hypotension risk) 4
- Reduce dose to 1-2 mg TID when adding other antihypertensives 4
Adverse Effects
- First-dose syncope (30-90 minutes post-dose) 4
- Orthostatic hypotension and dizziness (most common) 2
- Priapism (rare but requires immediate medical attention if erection >4 hours) 4
- Generally well-tolerated with low discontinuation rates 2
When to Use Prazosin
Consider prazosin when:
- PTSD is dominated by nightmares and insomnia 5
- Patient has failed or is unresponsive to trauma-focused psychotherapy 5
- Evidence-based pharmacotherapies (antidepressants) have been inadequate 5
- Obstructive sleep apnea has been excluded 5
Use as a targeted, time-limited trial with clear monitoring of sleep-specific benefits 5.
Common Pitfalls
- Starting at too high a dose - Always begin at 1 mg to minimize syncope risk
- Inadequate dose titration - Many patients, especially military veterans, require higher doses (10-15 mg) for efficacy
- Ignoring antidepressant interactions - Consider whether concurrent SSRIs may be limiting response
- Premature discontinuation - Allow 3-9 weeks for full therapeutic effect
- Failing to monitor blood pressure - Essential during titration phase
Alternative Agents
If prazosin is not tolerated or effective, other alpha-1 blockers (doxazosin, terazosin, tamsulosin) may be considered based on case reports, though RCT evidence is lacking 6.